Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Vir Biotechnology Q1 2024 GAAP EPS $(0.48) Beats $(1.07) Estimate, Sales $56.400M Beat $11.712M Estimate

Author: Benzinga Newsdesk | May 02, 2024 04:10pm
Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(1.07) by 55.14 percent. The company reported quarterly sales of $56.400 million which beat the analyst consensus estimate of $11.712 million by 381.54 percent. This is a 10.42 percent decrease over sales of $62.957 million the same period last year.

Posted In: VIR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist